These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 8033146)
21. Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy. Debes A; Willers R; Göbel U; Wessalowski R Pediatr Blood Cancer; 2005 Oct; 45(5):663-9. PubMed ID: 15929134 [TBL] [Abstract][Full Text] [Related]
22. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806 [TBL] [Abstract][Full Text] [Related]
23. Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction. Hayashi S; Hatashita M; Matsumoto H; Jin ZH; Shioura H; Kano E Int J Mol Med; 2005 Sep; 16(3):381-7. PubMed ID: 16077943 [TBL] [Abstract][Full Text] [Related]
24. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A. Vichi PJ; Tritton TR Cancer Res; 1993 Nov; 53(21):5237-43. PubMed ID: 8106144 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression. Hashimoto H; Chatterjee S; Berger NA Cancer Res; 1995 Sep; 55(18):4029-35. PubMed ID: 7664276 [TBL] [Abstract][Full Text] [Related]
26. Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16). Tronov VA; Konoplyannikov MA; Nikolskaya TA; Konstantinov EM Biochemistry (Mosc); 1999 Mar; 64(3):345-52. PubMed ID: 10205305 [TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Beere HM; Chresta CM; Hickman JA Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634 [TBL] [Abstract][Full Text] [Related]
28. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130 [TBL] [Abstract][Full Text] [Related]
29. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851 [TBL] [Abstract][Full Text] [Related]
30. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F; Bae I; Fornace AJ; Pommier Y Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795 [TBL] [Abstract][Full Text] [Related]
31. Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Chatterjee S; Trivedi D; Petzold SJ; Berger NA Cancer Res; 1990 May; 50(9):2713-8. PubMed ID: 2328496 [TBL] [Abstract][Full Text] [Related]
32. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166 [TBL] [Abstract][Full Text] [Related]
33. Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines. Dorr RT; Liddil JD; Gerner EW Cancer Res; 1986 Aug; 46(8):3891-5. PubMed ID: 3015379 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Gantchev TG; Hunting DJ Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822 [TBL] [Abstract][Full Text] [Related]
36. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
37. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198 [TBL] [Abstract][Full Text] [Related]
38. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid. De Graff WG; Myers LS; Mitchell JB; Hahn SM Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789 [TBL] [Abstract][Full Text] [Related]
39. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer. Wang SJ; Peyrollier K; Bourguignon LY Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087 [TBL] [Abstract][Full Text] [Related]
40. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]